{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:17:23Z","timestamp":1789917443440,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ITI (International team for Implantology) Scholarship Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00784-018-2349-6","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T01:05:48Z","timestamp":1517447148000},"page":"2527-2534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro"],"prefix":"10.1007","volume":"22","author":[{"given":"Junho","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Righesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Max","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Al-Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Dae","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"issue":"22","key":"2349_CR1","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long? N Engl J Med 366(22):2051\u20132053. https:\/\/doi.org\/10.1056\/NEJMp1202623","journal-title":"N Engl J Med"},{"issue":"10","key":"2349_CR2","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A, European Myeloma N (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254\u20131266. https:\/\/doi.org\/10.3324\/haematol.2014.117176","journal-title":"Haematologica"},{"issue":"5","key":"2349_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30(5):929\u2013933. https:\/\/doi.org\/10.1002\/jbmr.2410","journal-title":"J Bone Miner Res"},{"key":"2349_CR4","doi-asserted-by":"publisher","first-page":"15824","DOI":"10.1016\/j.pharmthera.2015.11.008","volume":"158","author":"HH Acker Van","year":"2016","unstructured":"Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF (2016) Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther 158:15824\u201315840. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.11.008","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2349_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40902-016-0099-4","volume":"39","author":"WS Choi","year":"2017","unstructured":"Choi WS, Lee JI, Yoon HJ, Min CK, Lee SH (2017) Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. Maxillofac Plast Reconstr Surg 39(1):1. https:\/\/doi.org\/10.1186\/s40902-016-0099-4","journal-title":"Maxillofac Plast Reconstr Surg"},{"issue":"9","key":"2349_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3109\/07357907.2010.512598","volume":"28","author":"J Green","year":"2010","unstructured":"Green J, Lipton A (2010) Anticancer properties of zoledronic acid. Cancer Investig 28(9):944\u2013957. https:\/\/doi.org\/10.3109\/07357907.2010.512598","journal-title":"Cancer Investig"},{"issue":"4","key":"2349_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3892\/or.2011.1152","volume":"25","author":"T Tamura","year":"2011","unstructured":"Tamura T, Shomori K, Nakabayashi M, Fujii N, Ryoke K, Ito H (2011) Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. Oncol Rep 25(4):1139\u20131143. https:\/\/doi.org\/10.3892\/or.2011.1152","journal-title":"Oncol Rep"},{"issue":"2","key":"2349_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","volume":"48","author":"V Stresing","year":"2011","unstructured":"Stresing V, Fournier PG, Bellahcene A, Benzaid I, Monkkonen H, Colombel M, Ebetino FH, Castronovo V, Clezardin P (2011) Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 48(2):259\u2013266. https:\/\/doi.org\/10.1016\/j.bone.2010.09.035","journal-title":"Bone"},{"issue":"2","key":"2349_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","volume":"57","author":"DK Wysowski","year":"2013","unstructured":"Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone 57(2):423\u2013428. https:\/\/doi.org\/10.1016\/j.bone.2013.09.008","journal-title":"Bone"},{"issue":"10","key":"2349_CR10","first-page":"475","volume":"5","author":"IJ Diel","year":"2007","unstructured":"Diel IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5(10):475\u2013482","journal-title":"J Support Oncol"},{"issue":"9","key":"2349_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115\u20131117. https:\/\/doi.org\/10.1016\/S0278-2391(03)00720-1","journal-title":"J Oral Maxillofac Surg"},{"issue":"8","key":"2349_CR12","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/j.jcms.2011.10.024","volume":"40","author":"Y Acil","year":"2012","unstructured":"Acil Y, Moller B, Niehoff P, Rachko K, Gassling V, Wiltfang J, Simon MJ (2012) The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg 40(8):e229\u2013e235. https:\/\/doi.org\/10.1016\/j.jcms.2011.10.024","journal-title":"J Craniomaxillofac Surg"},{"issue":"5","key":"2349_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.joms.2011.05.002","volume":"70","author":"D Marolt","year":"2012","unstructured":"Marolt D, Cozin M, Vunjak-Novakovic G, Cremers S, Landesberg R (2012) Effects of pamidronate on human alveolar osteoblasts in vitro. J Oral Maxillofac Surg 70(5):1081\u20131092. https:\/\/doi.org\/10.1016\/j.joms.2011.05.002","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"2349_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.joms.2013.08.007","volume":"72","author":"NM McLeod","year":"2014","unstructured":"McLeod NM, Moutasim KA, Brennan PA, Thomas G, Jenei V (2014) In vitro effect of bisphosphonates on oral keratinocytes and fibroblasts. J Oral Maxillofac Surg 72(3):503\u2013509. https:\/\/doi.org\/10.1016\/j.joms.2013.08.007","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"2349_CR15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","volume":"33","author":"D Amin","year":"1992","unstructured":"Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33(11):1657\u20131663","journal-title":"J Lipid Res"},{"issue":"1","key":"2349_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/0006-291X(92)91574-A","volume":"189","author":"MJ Rogers","year":"1992","unstructured":"Rogers MJ, Russell RG, Blackburn GM, Williamson MP, Watts DJ (1992) Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 189(1):414\u2013423. https:\/\/doi.org\/10.1016\/0006-291X(92)91574-A","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2349_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers MJ, Crockett JC, Coxon FP, Monkkonen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49(1):34\u201341. https:\/\/doi.org\/10.1016\/j.bone.2010.11.008","journal-title":"Bone"},{"issue":"17","key":"2349_CR18","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K, American Society of Clinical O (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464\u20132472. https:\/\/doi.org\/10.1200\/JCO.2007.12.1269","journal-title":"J Clin Oncol"},{"issue":"9","key":"2349_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","volume":"44","author":"T Boonyapakorn","year":"2008","unstructured":"Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44(9):857\u2013869. https:\/\/doi.org\/10.1016\/j.oraloncology.2007.11.012","journal-title":"Oral Oncol"},{"issue":"5","key":"2349_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","volume":"54","author":"C Walter","year":"2008","unstructured":"Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066\u20131072. https:\/\/doi.org\/10.1016\/j.eururo.2008.06.070","journal-title":"Eur Urol"},{"issue":"2","key":"2349_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5114\/aoms.2015.50964","volume":"11","author":"M Kos","year":"2015","unstructured":"Kos M (2015) Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci 11(2):319\u2013324. https:\/\/doi.org\/10.5114\/aoms.2015.50964","journal-title":"Arch Med Sci"},{"issue":"34","key":"2349_CR22","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580\u20138587. https:\/\/doi.org\/10.1200\/JCO.2005.02.8670","journal-title":"J Clin Oncol"},{"issue":"6","key":"2349_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826\u2013836. https:\/\/doi.org\/10.1359\/jbmr.080205","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2349_CR24","first-page":"968","volume":"91","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7):968\u2013971","journal-title":"Haematologica"},{"issue":"3","key":"2349_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65(3):415\u2013423. https:\/\/doi.org\/10.1016\/j.joms.2006.10.061","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"2349_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","volume":"72","author":"M Ulmner","year":"2014","unstructured":"Ulmner M, Jarnbring F, Torring O (2014) Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 72(1):76\u201382. https:\/\/doi.org\/10.1016\/j.joms.2013.06.221","journal-title":"J Oral Maxillofac Surg"},{"issue":"8","key":"2349_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","volume":"137","author":"American Dental Association Council on Scientific A","year":"2006","unstructured":"American Dental Association Council on Scientific A (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137(8):1144\u20131150","journal-title":"J Am Dent Assoc"},{"issue":"9 Suppl","key":"2349_CR28","doi-asserted-by":"publisher","first-page":"212S","DOI":"10.1177\/0022034515587862","volume":"94","author":"JW Kwon","year":"2015","unstructured":"Kwon JW, Park EJ, Jung SY, Sohn HS, Ryu H, Suh HS (2015) A large national cohort study of the association between bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis: a nested case-control study. J Dent Res 94(9 Suppl):212S\u2013219S. https:\/\/doi.org\/10.1177\/0022034515587862","journal-title":"J Dent Res"},{"issue":"2","key":"2349_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1601-0825.2010.01720.x","volume":"17","author":"C Walter","year":"2011","unstructured":"Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B (2011) Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis 17(2):194\u2013199. https:\/\/doi.org\/10.1111\/j.1601-0825.2010.01720.x","journal-title":"Oral Dis"},{"issue":"14","key":"2349_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4161\/cbt.22274","volume":"13","author":"G Misso","year":"2012","unstructured":"Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M (2012) Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther 13(14):1491\u20131500. https:\/\/doi.org\/10.4161\/cbt.22274","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2349_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jcms.2014.12.008","volume":"43","author":"FJ Manzano-Moreno","year":"2015","unstructured":"Manzano-Moreno FJ, Ramos-Torrecillas J, De Luna-Bertos E, Ruiz C, Garcia-Martinez O (2015) High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg 43(3):396\u2013401. https:\/\/doi.org\/10.1016\/j.jcms.2014.12.008","journal-title":"J Craniomaxillofac Surg"},{"key":"2349_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-29242-2","volume-title":"Arzneiverordnungs-Report 2012: Aktuelle Daten, Kosten, Trends und Kommentare","author":"UPD Schwabe","year":"2012","unstructured":"Schwabe UPD (2012) Arzneiverordnungs-Report 2012: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-29242-2"},{"issue":"9","key":"2349_CR33","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00784-014-1205-6","volume":"18","author":"C Walter","year":"2014","unstructured":"Walter C, Sagheb K, Bitzer J, Rahimi-Nedjat R, Taylor KJ (2014) Analysis of reasons for osteonecrosis of the jaws. Clin Oral Investig 18(9):2221\u20132226. https:\/\/doi.org\/10.1007\/s00784-014-1205-6","journal-title":"Clin Oral Investig"},{"issue":"6","key":"2349_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00223-013-9711-0","volume":"92","author":"JE Fisher","year":"2013","unstructured":"Fisher JE, Rosenberg E, Santora AC, Reszka AA (2013) In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorption. Calcif Tissue Int 92(6):531\u2013538. https:\/\/doi.org\/10.1007\/s00223-013-9711-0","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2349_CR35","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1016\/j.joms.2010.07.017","volume":"68","author":"S Otto","year":"2010","unstructured":"Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68(11):2837\u20132845. https:\/\/doi.org\/10.1016\/j.joms.2010.07.017","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"2349_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.joen.2014.07.010","volume":"41","author":"CA Martins","year":"2015","unstructured":"Martins CA, Leyhausen G, Volk J, Geurtsen W (2015) Effects of alendronate on osteoclast formation and activity in vitro. J Endod 41(1):45\u201349. https:\/\/doi.org\/10.1016\/j.joen.2014.07.010","journal-title":"J Endod"},{"issue":"3","key":"2349_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","volume":"58","author":"BJ Gertz","year":"1995","unstructured":"Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58(3):288\u2013298. https:\/\/doi.org\/10.1016\/0009-9236(95)90245-7","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00784-018-2349-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-018-2349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-018-2349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T18:18:25Z","timestamp":1660414705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00784-018-2349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2349"],"URL":"https:\/\/doi.org\/10.1007\/s00784-018-2349-6","relation":{},"ISSN":["1432-6981","1436-3771"],"issn-type":[{"value":"1432-6981","type":"print"},{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"29 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}